Litcius/Paper detail

POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS

David Jayne, B.H. Rovin, Eduardo Mysler, Richard Furie, Frédéric Houssiau, Teodora Trasieva, J. Knagenhjelm, Erik Schwetje, Yen Lin Chia, Raj Tummala, Catharina Lindholm

2021Annals of the Rheumatic Diseases16 citationsDOIOpen Access PDF

Topics & Concepts

MedicineLupus nephritisPlaceboClinical endpointInternal medicineRegimenInterim analysisGastroenterologyUrologyRandomized controlled trialPathologyDiseaseAlternative medicineSystemic Lupus Erythematosus ResearchRenal Diseases and GlomerulopathiesMonoclonal and Polyclonal Antibodies Research
POS0690 RANDOMIZED, CONTROLLED, PHASE 2 TRIAL OF TYPE 1 IFN INHIBITOR ANIFROLUMAB IN PATIENTS WITH ACTIVE PROLIFERATIVE LUPUS NEPHRITIS | Litcius